-
1
-
-
0032189117
-
Treatment of breast cancer
-
DOI 10.1056/NEJM199810013391407
-
Hortobagyi GN: Treatment of breast cancer. N Engl J Med 339:974-984, 1998. (Pubitemid 28455101)
-
(1998)
New England Journal of Medicine
, vol.339
, Issue.14
, pp. 974-984
-
-
Hortobagyi, G.N.1
-
2
-
-
34548144485
-
Tamoxifen for early breast cancer
-
Early Breast Cancer Trialists' Collaborative Group
-
Early Breast Cancer Trialists' Collaborative Group: Tamoxifen for early breast cancer. Cochrane Database Syst Rev 1:CD000486, 2001.
-
(2001)
Cochrane Database Syst Rev
, vol.1
-
-
-
3
-
-
0141576783
-
Meeting highlights: Updated international expert consensus on the primary therapy of early breast cancer
-
DOI 10.1200/JCO.2003.04.576
-
Goldhirsch A, Wood WC, Gelber RD, et al: Meeting highlights: updated international expert consensus on the primary therapy of early breast cancer. J Clin Oncol 21:3357-3365, 2003. (Pubitemid 46606270)
-
(2003)
Journal of Clinical Oncology
, vol.21
, Issue.17
, pp. 3357-3365
-
-
Goldhirsch, A.1
Wood, W.C.2
Gelber, R.D.3
Coates, A.S.4
Thurlimann, B.5
Senn, H.-J.6
-
4
-
-
0035869407
-
Use of chemotherapy plus a monoclonal antibody against her2 for metastatic breast cancer that overexpresses HER2
-
DOI 10.1056/NEJM200103153441101
-
Slamon DJ, Leyland-Jones B, Shak S, et al: Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344:783-792, 2001. (Pubitemid 32222155)
-
(2001)
New England Journal of Medicine
, vol.344
, Issue.11
, pp. 783-792
-
-
Slamon, D.J.1
Leyland-Jones, B.2
Shak, S.3
Fuchs, H.4
Paton, V.5
Bajamonde, A.6
Fleming, T.7
Eiermann, W.8
Wolter, J.9
Pegram, M.10
Baselga, J.11
Norton, L.12
-
5
-
-
0031926839
-
Effect of preoperative chemotherapy on the outcome of women with operable breast cancer
-
Fisher B, Bryant J, Wolmark N, et al: Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol 16:2672-2685, 1998. (Pubitemid 28363030)
-
(1998)
Journal of Clinical Oncology
, vol.16
, Issue.8
, pp. 2672-2685
-
-
Fisher, B.1
Bryant, J.2
Wolmark, N.3
Mamounas, E.4
Brown, A.5
Fisher, E.R.6
Wickerham, D.L.7
Begovic, M.8
DeCillis, A.9
Robidoux, A.10
Margolese, R.G.11
Cruz Jr., A.B.12
Hoehn, J.L.13
Lees, A.W.14
Dimitrov, N.V.15
Bear, H.D.16
-
6
-
-
0035751675
-
Preoperative chemotherapy in patients with operable breast cancer: Nine-year results from national surgical adjuvant breast and bowel project B-18
-
Wolmark N, Wang J, Mamounas E, et al: Preoperative chemotherapy in patients with operable breast cancer: nine-year results from National Surgical Adjuvant Breast and Bowel Project B-18. J Natl Cancer Inst Monogr 30:96-102, 2001.
-
(2001)
J Natl Cancer Inst Monogr
, vol.30
, pp. 96-102
-
-
Wolmark, N.1
Wang, J.2
Mamounas, E.3
-
7
-
-
0642347622
-
The effect of tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: Preliminary results from national surgical adjuvant breast and bowel project protocol B-27
-
Bear HD, Anderson S, Brown A, et al: The effect of tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: Preliminary results from National Surgical Adjuvant Breast and Bowel Project protocol B-27. J Clin Oncol 2003.
-
(2003)
J Clin Oncol
-
-
Bear, H.D.1
Anderson, S.2
Brown, A.3
-
8
-
-
0037832780
-
Decision tree and paradigms of primary breast cancer: Changes elicited by preoperative therapy
-
Toi M, Bando H, Saji S: Decision tree and paradigms of primary breast cancer: Changes elicited by preoperative therapy. Med Sci Monit 9:90-95, 2003.
-
(2003)
Med Sci Monit
, vol.9
, pp. 90-95
-
-
Toi, M.1
Bando, H.2
Saji, S.3
-
9
-
-
27144533720
-
-
ASCO meeting
-
Buzdar AU, Hunt K, Smith T, Francis D, Ewer M, Booser D, Singletary E, Buchholz T, Sahin A, Hortobagyi GN: Significantly higher pathological complete remission (PCR) rate following neoadjuvant therapy with trastuzumab (H), paclitaxel (P), and anthracycline-containing chemotherapy (CT): Initial results of a randomized trial in operable breast cancer (BC) with HER/2 positive disease Abstract 520, 2004 ASCO meeting.
-
(2004)
Significantly Higher Pathological Complete Remission (PCR) Rate Following Neoadjuvant Therapy with Trastuzumab (H), Paclitaxel (P), and Anthracycline-containing Chemotherapy (CT): Initial Results of a Randomized Trial in Operable Breast Cancer (BC) with HER/2 Positive Disease Abstract
, vol.520
-
-
Buzdar, A.U.1
Hunt, K.2
Smith, T.3
Francis, D.4
Ewer, M.5
Booser, D.6
Singletary, E.7
Buchholz, T.8
Sahin, A.9
Hortobagyi, G.N.10
-
10
-
-
1542545085
-
Clinical trial methods to discover and validate predictive markers for treatment response in cancer
-
DOI 10.1016/S1387-2656(03)09005-7
-
Paik S: Clinical trial methods to discover and validate predictive markers for treatment response in cancer. Biotechnol Annu Rev 9:259-267, 2003. (Pubitemid 41085858)
-
(2003)
Biotechnology Annual Review
, vol.9
, pp. 259-267
-
-
Paik, S.1
-
11
-
-
3042819228
-
Modulation of thymidine phosphorylase by neoadjuvant chemotherapy in primary breast cancer
-
Toi M, Bando H, Horiguchi S, Takada M, Kataoka A, Ueno T, Saji S, Muta M, Funata N, Ohno S: Modulation of thymidine phosphorylase by neoadjuvant chemotherapy in primary breast cancer. Br J Cancer 90:2338-2343, 2004. (Pubitemid 38961897)
-
(2004)
British Journal of Cancer
, vol.90
, Issue.12
, pp. 2338-2343
-
-
Toi, M.1
Bando, H.2
Horiguchi, S.3
Takada, M.4
Kataoka, A.5
Ueno, T.6
Saji, S.7
Muta, M.8
Funata, N.9
Ohno, S.10
-
12
-
-
0141844522
-
Regulation of cyclooxgenase-2 mRNA stability by taxanes: Evidence for involvement of p38, MAPKAPK-2, and HuR
-
DOI 10.1074/jbc.M301481200
-
Subbaramaiah K, Marmo TP, Dixon DA, Dannenberg AJ: Regulation of cyclooxgenase-2 mRNA stability by taxanes: evidence for involvement of p38, MAPKAPK-2, and HuR. J Biol Chem 278:37637-37647, 2003. (Pubitemid 37175287)
-
(2003)
Journal of Biological Chemistry
, vol.278
, Issue.39
, pp. 37637-37647
-
-
Subbaramaiah, K.1
Marmo, T.P.2
Dixon, D.A.3
Dannenberg, A.J.4
-
13
-
-
2142647373
-
Nuclear factor-κB mediates up-regulation of cathepsin B by doxorubicin in tumor cells
-
DOI 10.1124/mol.65.5.1092
-
Bien S, Ritter CA, Gratz M, Sperker B, Sonnemann J, Beck JF, Kroemer HK: Nuclear factor-kappaB mediates up-regulation of cathepsin B by doxorubicin in tumor cells. Mol Pharmacol 65:1092-1102, 2004. (Pubitemid 38543480)
-
(2004)
Molecular Pharmacology
, vol.65
, Issue.5
, pp. 1092-1102
-
-
Bien, S.1
Ritter, C.A.2
Gratz, M.3
Sperker, B.4
Sonnemann, J.5
Beck, J.F.6
Kroemer, H.K.7
-
14
-
-
0242710172
-
Celecoxib anti-aromatase neoadjuvant (CAAN) trial for locally advanced breast cancer: Preliminary report
-
DOI 10.1016/S0960-0760(03)00355-8
-
Chow LW, Wong JL, Toi M: Celecoxib anti-aromatase neoadjuvant (CAAN) trial for locally advanced breast cancer: preliminary report. J Steroid Biochem Mol Biol 86:443-447, 2003. (Pubitemid 37412582)
-
(2003)
Journal of Steroid Biochemistry and Molecular Biology
, vol.86
, Issue.3-5
, pp. 443-447
-
-
Chow, L.W.C.1
Wong, J.L.N.2
Toi, M.3
-
15
-
-
84858048365
-
Postoperative adjuvant therapy with tamoxifen, tegafur-uracil (UFT) or both in women with node-negative breast cancer. A pooled analysis of six randomized controlled trials ACETBC 4th trial
-
Ikeda T, Uchino J, Abe R, Miura S, Koyama H, Sugimachi K, Akazawa K, Abe O: Postoperative adjuvant therapy with tamoxifen, tegafur-Uracil (UFT) or both in women with node-negative breast cancer. A pooled analysis of six randomized controlled trials ACETBC 4th trial. Breast 12:76, 2003.
-
(2003)
Breast
, vol.12
, pp. 76
-
-
Ikeda, T.1
Uchino, J.2
Abe, R.3
Miura, S.4
Koyama, H.5
Sugimachi, K.6
Akazawa, K.7
Abe, O.8
|